比斯穆特药物通过有氧呼吸消除了对多种药物耐药的Burkholderia cepacia复合体
Jingru Li1,2, Haibo Wang1, Peng Gao3
1Department of Chemistry, The University of Hong Kong Hong Kong SAR P. R. China hsun@hku.hk.
在治疗囊性纤维化患者的抗生素耐药Burkholderia cepacia复合体 (Bcc) 感染方面,树木药物显示出前途. 这些化合物抑制BCC生长,生物膜和持久性,提供了潜在的新治疗途径.
科学领域:
- 微生物学 微生物学
- 传染性疾病 传染性疾病
- 药物发现 药物发现 药物发现
背景情况:
- 伯克霍德里亚塞帕西亚综合体 (Bcc) 在囊性纤维化 (CF) 患者中引起慢性肺部感染.
- Bcc对多种抗生素表现出内在的耐药性,使治疗复杂化.
- 目前的治疗方法往往无法在慢性感染的个体中根除BCC.
研究的目的:
- 为了研究对抗多药耐药性BCC菌株的比斯木特药物的疗效.
- 探索斯木对Bcc.的作用机制.
- 在临床前模型中评估斯木的治疗潜力.
主要方法:
- 最低抑制度 (MIC) 对临床Bcc分离物的测定.
- 生物膜和持久性细胞敏感性测试.
- 在体内疗效的Galleria mellonella感染模型.
- 转录组学和金属保护组学以阐明机制.
主要成果:
- 比斯穆特药物抑制了抗生素耐药Bcc菌株的生长 (MIC~25μg/mL).
- 比斯穆特对BCC生物膜和持久性表现出强烈的活性.
- 在体内研究表明,在Galleria mellonella模型中~50%的生存率.
- 石向TCA循环,氧化酸化和蛋白质翻译.
结论:
- 比斯穆特药物对抗多抗药性BCC有效.
- 石准了BCC中的重要代谢和细胞过程.
- 比斯穆特代表了CF中Bcc感染的有前途的治疗策略.
更多相关视频
07:46Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
07:16Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
Published on: September 20, 2024
相关概念视频
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Development of Antibiotic Resistance
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Gene Regulation in Microbial Communities: Quorum Sensing
